| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790371 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Toxicity-related dose reduction is a common event in mRCC patients who have started first-line therapy with either sunitinib or pazopanib. This is positively related to the outcomes of both first- and second-line therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Roberto M.D., Ph.D., Maria M.D., Luca M.D., Ugo M.D., Ph.D., Roberto M.D., Matteo M.D., Ph.D., Alessandra M.D., Ph.D., Giuseppe M.D., Francesco M.D., Cristina M.D., Melissa M.D., Elisa M.D., Cristian M.D., Annalisa M.D., Rossana M.D., Carlo M.D.,